Organic Active Ingredients TRIZ Cases

Combining a substituted pyrazole CDK4/6 inhibitor with endocrine therapy helps cut recurrence risk in HR+/HER2- early breast cancer.

A polysiloxane adhesive matrix with solubilizer and propylene glycol improves THC skin permeation and maintains continuous transdermal flux.

An AG5 andrographolide derivative suppresses multiple cytokines and neutrophil migration while avoiding the toxicity of antibody-based cytokine storm treatments.

A balanced crystalloid ammonium sulfate gradient boosts extracellular vesicle drug loading while avoiding precipitation and preserving exosome activity.

Salt conversion to a sulfate crystal improves MNK inhibitor solubility, lowers oxidation risk, and supports easier production and storage.

Novel cyclopentapyrrole and azabicycloheptane agonists improve orexin receptor targeting for potential treatment of neurological and psychiatric disorders.

Sulfonic acid counter-ions keep tranexamic acid ester salts uniformly dispersed in skin compositions without crystallization or added stabilizers.

Small-molecule GLP-1R modulators address the injection-to-oral tradeoff by preserving agonist activity for obesity, NASH, and Type 2 diabetes.

Reduced-pressure Maillard coating with de-oiled lecithin protects PUFAs from rumen biohydrogenation and improves milk and meat fatty acid profiles.

Irinotecan-loaded mesoporous silica nanoparticles target cancer cells to curb metastasis, improve delivery, and reduce side effects.

Nitrogen heterocyclic compounds covalently bind KRAS G12C, create a new pocket, and lock the protein in an inactive state for cancer treatment.

An alcohol-propylene glycol aqueous dronabinol solution improves room-temperature stability and delivers faster, more consistent oral absorption.

Selective topical PI3K/mTOR compounds improve skin penetration and stability while reducing systemic side effects in long-term skin disorder treatment.

Glyburide analog compositions enhance autophagy to clear misfolded protein aggregates and reduce cellular damage in autophagy-associated disease.

Combining a thioether-linked antibody-drug conjugate with paclitaxel or eribulin boosts antitumor activity by suppressing resistance factors.

Young watermelon compounds Citrulluside H and T reduce ROS, inhibit MMP-1 and AP-1 activity, and support safe anti-skin aging use.

Targeting the Nrf2/HO-1 axis with dimethyl or monomethyl fumarate boosts IL-10 and reduces macrophage activation syndrome symptoms.

Compounds that stabilize vascular endothelium help prevent hemorrhage, vascular instability, and blood-brain barrier disruption during thrombolytic therapy.

A stabilized oxazine HBr salt and in situ synthesis reduce harmful impurities, while a hydrochloride 1.5 hydrate stabilizes oral dosing.

Modified oligonucleotides lower thrombopoietin activity while keeping platelet counts in a safe range for disease management.

Targeted ADC depletion of recipient stem cells plus JAK inhibition enables alloHSCT engraftment with lower toxicity than chemotherapy or irradiation.

Combining magnesium salts or chelates with ascorbate improves GI absorption by at least 55% while reducing gastrointestinal side effects.

Selective and dual Factor XIa-plasma kallikrein inhibitors help control abnormal coagulation while improving thrombosis treatment flexibility.

Unnatural base pairs are incorporated in vivo to expand nucleic acid chemical diversity while preserving polymerase-compatible stability and function.

A solid GDL-HPMC vaginal tablet solves the instability of liquid gluconic acid while enabling slow release, biofilm reduction, and low side effects.

Selective caries removal, pulp capping, and staged follow-up relieve symptomatic pulpal pain while preserving vitality and avoiding overtreatment.

Selective M4 antagonists expand BFU-E progenitors to improve erythrocyte production in anemia cases where erythropoietin is ineffective.

Combining auristatin-based ADCs with PI3K-AKT-mTOR inhibitors overcomes pathway complexity to improve tumor cell killing and growth control.

Tetracyclic compounds act prophylactically and therapeutically against Zika virus, helping block infection and slow disease progression.

Using yeast ascospores as the chitosan source avoids shellfish contaminants and deacetylation, enabling cleaner production for food and therapeutic use.

Insoluble coating particles and a dilute binder form stable granules that resist segregation and keep mixtures uniform at high productivity.

Predetermined linker length and diameter help PSMA conjugates deliver therapeutic or imaging agents to prostate cancer cells while limiting off-target effects.

A low-GWP HFO-1234ze epinephrine MDI uses ethanol and polysorbate 80 to keep the suspension stable and delivery consistent.

Chemically modified APOC3 siRNA conjugates improve stability and sustain gene silencing to lower blood lipids in dyslipidemia.

HSD3B1 genotype and 3β-HSD1 protein testing guide corticosteroid or non-corticosteroid selection to reduce asthma under- and over-treatment.

Novel small-molecule Drp1 inhibitors improve selectivity and oral bioavailability while reducing mitochondrial fission linked to disease.

Targeting LTA4H with benzodioxane inhibitors modulates leukotriene production to improve cognition and reduce age-related neuroinflammation.

Lewis acid mediated coupling improves regioselective pyrimidinyl-4-aminopyrazole synthesis for LRRK2 inhibitor intermediates.

Swirling airflow rotates the capsule to aerosolize powder at smoking-like inhalation rates while the modular cavity supports easy capsule replacement.

Substituted indole compounds activate IDO1 and help preserve its ferrous activity in cells, improving immune regulation in autoimmune disorders.

A U7-based snRNA targets USH2A pre-mRNA to skip Exon 13 more precisely than AON, avoiding frameshift risk and easing large-gene delivery limits.

Preformed HDL-like nanodiscs protect peptides and nucleic acids from degradation while improving co-delivery to lymphoid tissues.

A base-catalyzed synthesis and controlled crystallization route raises Jaktinib dihydrochloride purity above 99.0% while limiting mutagenic impurities.

Novel AR-targeting PROTAC compounds use segmented ligands and linker tuning to improve solubility, metabolic stability, and AR degradation.

Controlled oral minoxidil release over 12 hours helps treat hair loss while lowering peak adverse effects and improving compliance.

A combined isoquercetin, vitamin B3, and vitamin C regimen inhibits PDI to reduce thrombo-inflammatory vasculopathy in sickle cell disease.

Cell membrane nanoparticles use an isotonic inner core plus steroid and sphingolipid enrichment to improve stability and therapeutic delivery.

Gene expression profiling of NRF2 splice variants and downstream targets helps identify NRF2-dependent cancers and guide antagonist-based treatment.

A topical midostaurin formulation lowers tyrosinase activity and melanin with less irritation and toxicity than conventional hyperpigmentation therapies.

Synthetic lysine analogs block CDCP1 cleavage and p300 acetylation to inhibit cancer cell proliferation, metastasis, and survival.

3-Benzylpyridin-2-amine derivatives activate SSTR4 to address limited control of cortical and hippocampal neuronal activity in CNS disorders.

Pyrazolo[1,5-a]pyridine compounds inhibit MIF to address inadequate treatment options across malaria, cancer, and inflammatory disease.

Anti-LY75 antibodies combine with anti-CD20 antibodies or ibrutinib to target cancer cells and improve lymphoma and leukemia treatment efficacy.

Systematic substituent changes tune acylsulfonamide binding and selectivity for KAT6A, supporting therapeutic exploration in cancer and autoimmune disease.

Variable R1–R4 substituents adapt Formula I compounds to viral mutations while preserving inhibition of the conserved SARS-CoV-2 main protease.

Chloromethylenedimethyliminium chloride replaces the oxalyl chloride–DMF route, improving stoichiometric control and reducing yellow impurities.

Compound (1) provides early symptom improvement while a second antidepressant develops sustained efficacy for MDD or PPD.

Viral delivery of NeuroD1, Brn2, Ascl1, or Ngn2 pairs glioma-cell lysis with reprogramming into non-tumorigenic cells.

A buffered aqueous eye formulation uses a water-soluble chemical cross-linker to strengthen corneal collagen without UV exposure.

Seven-amino-acid peptide insertions modify AAV capsids to improve microglial transduction and transgene expression without immune activation.

See how a multi-substance homeopathic composition targets respiratory inflammation while preserving ciliated epithelium and mucociliary clearance.

Retinoid compositions address limited HFpEF treatment efficacy by reducing left ventricular stiffness and improving diastolic function.

PD-1 axis antagonists paired with taxanes enhance immune function and directly inhibit tumors, addressing insufficient control in metastatic breast cancer.

Chemotherapy can trigger SASP that promotes tumor growth; salvianolic acid E removes senescent cells and supports stronger tumor suppression.

Targeting midkine pre-mRNA, these SSOs induce exon 3 or 4 skipping to limit full-length MDK protein for disease treatment.

Denaturing SEC disrupts LNP shells for direct injection and reproducible nucleic acid measurement without pretreatment.

Antibodies targeting alpha-synuclein residues 112–117 bind truncated species, clear extracellular protein, and limit neuronal pathology spread.

Functional side chains modify Momordica saponins MS I and II, addressing QS-21 supply limits while improving antigen-specific IgG2a responses.

These steroid compounds modulate GABAA receptors to regulate brain excitability and support treatment of CNS disorders such as depression, schizophrenia, and seizures.

Systemic P2X7R antagonist dosing can exceed tolerable plasma levels; lymph node delivery targets hyperinflammation while limiting toxicity.

Tricyclic compounds such as nortriptyline and amitriptyline modulate SYNGAP1 expression to address treatment-resistant synaptic deficiencies.

AAV delivery of functional TK2 targets enzyme deficiency and nucleotide pool imbalance in mitochondrial DNA depletion syndromes.

Substance P receptor antagonists inhibit tau hyperphosphorylation, reducing hyperphosphorylated tau accumulation linked to CTE.

Selective extraction removes flavokavain A and B from kava, while micronization and irradiation improve kratom colloidal stability in solution.

Particle-size control and selected wetting and viscosity agents improve suspension stability and resuspendability for 30-gauge suprachoroidal injection.

Rigid 4–6-week fractionation can miss tumor changes; combining TTFields with PULSAR enables adaptive dosing while increasing radiation sensitivity.

Novel pyrazine-carboxamide derivatives address low mGluR4 activity and blood-brain barrier efflux through tailored molecular structures.

These compounds target aberrant APOL1 activity to reduce proteinuria and slow kidney function decline in FSGS and NDKD.

Distinct X-ray powder diffraction fingerprints identify voruciclib polymorphs while supporting improved stability and bioavailability.

Targeted MMP-9 antibodies, inhibitory RNAs, or CRISPR-Cas systems aim to limit FOP flare-ups and heterotopic ossification while avoiding broad-spectrum toxicity.

Parenteral HMW-HA suppresses M1 macrophage activity and promotes M2 polarization to reduce excessive immune responses and organ damage.

An ambient-temperature pH-gradient process loads weak-acid salts into liposomes, avoiding heat-driven degradation while improving retention.

Crystalline Ribociclib succinate forms target moisture absorption and polymorphic change, improving stability and pharmaceutical processing.

Non-aqueous solvents such as polyethylene glycol and dehydrated alcohol stabilize liquid bendamustine without antioxidant additives.

Improved metabolic stability and pharmacokinetics help these compounds inhibit HIV replication while supporting less frequent dosing.

pVip enzymes convert endogenous nucleotides into chain terminators that block viral replication and malignant-cell DNA synthesis.

FGFR1 and PDGFRA expression with TP53 status stratifies STS patients for pazopanib instead of treating likely non-responders.

Lipid nanoparticles use safflower oil, triacetin, and surfactants to solubilize hydrophobic therapeutics without toxic cosolvents.

Flexible linkers around a rigid biphenyldicarboxamide scaffold address α-helix mimicry and metabolic stability in selective Bcl-2 family binding.

Lipophilic moieties attached to 3-O-glucuronic acid help saponin adjuvants balance immune activity, stability, and toxicity.

D-ring substituents modify blebbistatin compounds to improve solubility and mutagenicity profiles while preserving myosin-2 inhibition.

Selective compounds target S1P1 and S1P5 receptors through orthosteric or allosteric agonism, addressing limited subtype precision.

A stepwise radiprodil titration regimen helps control pediatric seizures while limiting psychotomimetic side effects from non-selective NMDA antagonists.

Separate backing layers release aversive agents during extraction while keeping them away from skin during normal transdermal use.

Formula I and II compounds target ROCK2 selectively, addressing limited specificity while improving solubility and bioavailability.

Localized electrophilic warheads target a unique CDK2 lysine residue, balancing kinase selectivity with reversible binding and lower off-target reactivity.

Local substituent and stereochemical tuning delivers 10- to 100-fold PARP1 selectivity, limiting PARP2 off-target effects in HR-deficient tumors.

Periodic LVOT gradient and LVEF assessments guide dose changes or temporary discontinuation to limit systolic dysfunction and heart failure risk.

Chemical compounds and therapeutic formulations modulate HGF signaling to reduce fibrosis-associated inflammation and improve organ-function biomarkers.

Administered before, during, or after nephrotoxin exposure, Compound I reduces kidney injury markers and improves renal function.

Bicyclo compounds block indoleamine 2,3-dioxygenase to prevent tryptophan depletion and restore antitumor immune responses.

Ionizable polymeric stabilizers prevent agglomeration in hydrophobic API dispersions, improving nanoparticle stability and bioavailability.

Triazolopyridazine compounds reduce uncontrolled cell growth and metastasis by inhibiting cMET kinase activity.

Modifying bicyclic compound structures optimizes WRN inhibitor binding affinity and selectivity to treat mismatch repair deficient tumors.

Oligonucleotides suppress Map4k4 mRNA to resolve inadequate protein regulation, enhancing muscle fiber formation and mass.

Stratifying cancer patients using neutrophil counts and blast ratios to predict farnesyltransferase inhibitor responsiveness.

Structural parameter changes in quinoline cores resolve contradictions between receptor blocking activity and metabolic stability.

Adjust soluble beta-glucan doses based on anti-body levels to resolve inconsistent immunopharmacodynamic responses across diverse patient subgroups.

Collagen mediates urolithin stability, resolving degradation issues that conventional chelating agents fail to address.

M@P-WI nanospheres integrate photothermal heating with DDR2 inhibition to soften tumor matrices, enabling complete triple-negative breast cancer eradication.

Pyrimidine JAK inhibitors with oxetane moieties enable topical skin application, reducing systemic immunosuppression while treating inflammatory diseases.

6-substituted estradiol derivatives reduce systemic toxicity by selectively targeting estrogen receptors in both dependent and independent tumors.

MN-001 dosage ranges reduce elevated lipid levels while maintaining oral bioavailability and anti-inflammatory properties.

Multi-step chemical synthesis produces antiviral compounds using specific intermediates, reducing toxicity and side effects in hepatitis C treatments.

Ginkgolide B selectively inhibits the mTORC1 signaling pathway to extend lifespan and improve healthspan metrics.

Hydrogel carriers deliver calcineurin inhibitors and glucocorticoids locally, reducing systemic risks while promoting nerve regeneration.

A pharmaceutical composition disperses micronized active agents within a hydrophilic polymer matrix to control release kinetics.

Quinone methides reduce pathological vWF levels to balance clotting function and cardiovascular risk.

Indoline inhibitors target KIF18A to reduce tumor growth in preclinical models, addressing inadequate therapeutic options for cancer.

Adjusting dienogest particle size to 25-70 μm reduces steroid load while maintaining contraceptive effectiveness and homogeneity.

Segmenting prognostic assessment via gene expression levels resolves Gleason score inaccuracy for metastasis prediction.

Macrocyclic peptides inhibit the HCV NS3 protease to overcome viral genetic heterogeneity and sustain efficacy.

Differential oxidation levels on discrete carbon nanotube surfaces prevent agglomeration and enable uniform dispersion in polymer matrices.

Combining a mithramycin analogue with taxanes or nucleoside analogs overcomes resistance mechanisms while reducing toxicity compared to standard chemotherapy.

Phosphadiazine polymerase inhibitors reduce HCV viral load while minimizing side effects through structural optimization.

A fixed-ratio combination of lixisenatide and insulin glargine improves glycemic control in type 2 diabetes patients.

Titanium oxide and antioxidants shield anhydrous dasatinib from light-induced discoloration, maintaining photostability during storage.

Combining Salvia miltiorrhiza extract with niacin increases collagen expression to restore skin firmness.

Antisense RNA nanoparticles degrade PMP22 mRNA to restore locomotion and muscle strength, overcoming the toxicity of progesterone antagonists.

MAP4K4 inhibitors overcome lack of targeting specificity in cancer therapies by blocking tumor progression.

Methylation at the 2' position of the pyrrolidine ring increases affinity for alpha7 receptors while avoiding adverse effects from non-specific stimulation.

Alpha-hydroxy carboxylic acid moieties conjugate to opioids, creating prodrugs that reduce bioavailability and abuse potential.

Combines cabiralizumab and nivolumab to modulate the immune microenvironment in pancreatic cancer treatment.

Bifunctional compounds recruit E3 ubiquitin ligases to degrade FLT3, resolving non-specific effects in cancer therapy.

Pulsed ultrasound at 1.1 MPa opens the blood-brain barrier via acoustic cavitation, enabling therapeutic drug delivery without hemorrhages.

Optimized aqueous phase pH increases lipid nanoparticle mRNA loading capacity for microneedle administration.

Cannabidiol penetrates the blood-brain barrier to reduce microglia and astrocyte activation, addressing persistent neuroinflammation.

Targeting the angiotensinogen gene with double-stranded RNAi reduces blood pressure while avoiding kidney damage and side effects from multi-drug regimens.

Postbiotic extract preparation induces TGF-beta secretion to improve cartilage cell proliferation against progressive articular cartilage loss.

A lenalidomide liquid composition uses polyethylene glycol and propylene glycol to dissolve the drug completely.

Azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives inhibit Janus kinase activity while avoiding side effects from non-selective kinase inhibition.

Phenyl-uracil derivatives suppress viral replication to resolve the trade-off between sustained cure rates and severe treatment side effects.

RNAi agents reduce HSF1 expression, restoring chemotherapy sensitivity by removing heat shock protein-mediated resistance.

Segmented FTD/TPI administration prevents drug accumulation and toxicity while preserving antitumor activity in severe renal impairment.

Allosteric compounds bind wild-type CBFβ to displace RUNX1, overcoming the undruggable protein-protein interaction bottleneck in cancer therapy.

Fused aminodihydro-oxazine derivatives inhibit beta-site amyloid precursor protein cleaving enzyme 1, addressing underlying causes of neurodegeneration.